Key Takeaways The realistic goals of stem cell therapy for MS are slowing disease activity, reducing fatigue, and improving mobility, not reversing all past damage. Mesenchymal stem cells (MSCs) calm
Quick Summary A 2026 Nature study (MATCH trial) shows autologous macrophage therapy may improve transplant‑free survival in cirrhosis. After 4 years, ~70% of treated patients were alive without liver transplant
Quick Summary Family support is essential for recovery after cell-based therapy for hypoxic brain damage. Families help with daily rehabilitation exercises, motor function practice, medication schedules, and emotional support. Recovery
Quick Summary TreeFrog Therapeutics announced preclinical data for TFG‑001, a 3D neural microtissue therapy for Parkinson’s disease. The approach aims to replace damaged dopamine‑producing neurons. Preclinical models showed rapid dopamine
Quick Summary New 2026 Phase 2 data for BRTX-100 (autologous mesenchymal stem cell therapy for chronic lumbar disc disease) shows sustained pain and functional improvements at 52 weeks: 56% of
Quick Summary Stem cell therapy is making measured progress toward treating age-related diseases like vision loss, frailty, and Parkinson’s, but broad age reversal remains unproven. Recent clinical trials show improved
